Clinical Trials
43 trialsNCT02135874 2024-03-22
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02441803 2024-02-22
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03096782 2023-10-11
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02686593 2022-10-06
Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML
The University of Hong Kong
Phase 2 Completed
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT01119066 2022-08-05
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01451515 2022-06-28
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00042341 2022-05-27
Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)
Sanofi
Phase 2 Completed
NCT01025778 2021-02-21
Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia
Lund University Hospital
Phase 2 Completed
NCT00469014 2021-01-26
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00067028 2020-12-08
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01252667 2020-04-16
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00857389 2020-04-07
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01462253 2019-01-25
LAL1610
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00903760 2018-11-15
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00065143 2018-11-07
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01025154 2018-10-09
Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00990249 2018-08-07
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01444742 2018-07-03
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00201669 2017-12-06
A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00775593 2017-11-09
AML1107
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00945815 2017-11-06
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT01101880 2017-10-19
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
University of Washington
Phase 2 Completed
NCT01643668 2017-07-13
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
Phase 2 Completed
NCT01656031 2017-06-20
A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia
Wake Forest University Health Sciences
Phase 2 Completed
NCT01457885 2017-06-02
CloBu4
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00973752 2017-03-30
Treatment of Older Adults With Acute Lymphoblastic Leukemia
Massachusetts General Hospital
Phase 2 Completed
NCT00778375 2016-07-14
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00299156 2015-11-03
Oral Clofarabine Study in Patients With Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01295307 2015-10-07
BRIDGE
Technische Universität Dresden
Phase 2 Completed
NCT02544789 2015-09-09
Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
Betta Pharmaceuticals Co., Ltd.
Phase 2 Completed
NCT00924443 2015-04-01
A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable
Sanofi
Phase 2 Completed
NCT00098033 2015-03-25
Investigation of Clofarabine in Acute Leukemias
FDA Office of Orphan Products Development
Phase 2 Completed
NCT00337168 2015-03-25
S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00042354 2015-03-05
Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients
Sanofi
Phase 2 Completed
NCT00373529 2014-04-14
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
Sanofi
Phase 2 Completed
NCT00044889 2014-03-19
Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia
Sanofi
Phase 2 Completed
NCT00724009 2014-03-18
Clofarabine Bone Marrow Cytoreduction
University of Chicago
Phase 2 Completed
NCT00930098 2014-02-11
A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia
Sanofi
Phase 2 Completed
NCT00334074 2013-07-17
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS
Baylor Research Institute
Phase 2 Completed
NCT00852163 2013-04-04
Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen
Baylor Research Institute
Phase 2 Completed
NCT00088218 2012-08-07
Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00422032 2012-07-27
2 Arm Study of Clofarabine IV in MDS Patients
M.D. Anderson Cancer Center
Phase 2 Completed